Spegra Tablet

A doctor decides the recommended dose of Spegra 50/200/25mg Tablet according to your previous medical condition and response to the treatment. It is advised to take this medicine after consulting your healthcare expert. This medicine should be taken orally at the same time every day. Please do not crush or chew the medicine and eat it as a whole with a glass of water. This tablet can be taken with or without food.

Spegra Tablet is a combination of three medicines Dolutegravir, Emtricitabine and Tenofovir Alafenamide. It is antiretroviral or antiviral drug used to treat people diagnosed with HIV infection. This tablet works by inhibiting the replication process of HIV infection. It improves the immune system of the patient to fight against infection, controls the virus production, reduces the viral load in the body and slows down the growth of this disease and works on overall health.

It is advised not to miss any scheduled dosage of the Spegra 50/200/25mg Tablet. In case you miss a dose, consult your doctor immediately.

Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.

It is advised to use effective birth control methods to avoid pregnancy. Some drugs can cause birth defects, miscarriage, or death to an unborn baby if the mother or father is using this medicine. Moreover, this medicine may pass to the unborn baby.

Consult your doctor if you observe symptoms such as abdominal pain, loss of appetite, dark urine, or yellowing of the eyes or skin. These symptoms indicate the presence of Jaundice in the body.

It is advised to tell your doctor about all medicines (multivitamins, herbal supplements) you're taking currently before starting your course with Spegra 50/200/25mg Tablet. There are chances that many drugs can interact, and some drugs should not be used together.

Inform your healthcare expert in case of a history of severe blood infection, active tuberculosis, liver problems, or any serious health disorder.

1. Patel, H., Shah, M. P. A., Gajera, M. R. J., & Patel, H. D. (2021). DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF RELATED SUBSTANCES PRESENT IN THE PHARMACEUTICAL DOSAGE FORM OF EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND DOLUTEGRAVIR. Towards Excellence, 13(3).
2. Rathod, S. M., & Patel, P. U. (2022). Chemometrics-assisted spectrophotometric method development and validation for simultaneous estimation of emtricitabine, tenofovir alafenamide fumarate, and dolutegravir sodium in dosage form. Journal of Reports in Pharmaceutical Sciences, 11(1), 41-50.
3. Venter, W. D., Sokhela, S., Simmons, B., Moorhouse, M., Fairlie, L., Mashabane, N., ... & Hill, A. (2020). Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. The lancet HIV, 7(10), e666-e676.
4. Sax, P. E., Pozniak, A., Montes, M. L., Koenig, E., DeJesus, E., Stellbrink, H. J., ... & Quirk, E. (2017). Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. The Lancet, 390(10107), 2073-2082.
5. Deeks, E. D. (2018). Bictegravir/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection. Drugs, 78(17), 1817-1828.